£5m medicines savings schemes progressing

"Medicines savings (Medium risk) – (£5m). This includes continuation from 24/25 schemes, new schemes for 25/26 and the continued Rivaroxaban price reduction continuation. Further development is progressing on new schemes implementation to support in-year cashable savings."